Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $18.
July 30, 2024 | 10:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Arcutis Biotherapeutics and maintained a price target of $18.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100